Etanercept;依那西普
分子式:C2224H3472N618O701S36分子量:51.18KD
简介:Etanercept inhibits in vitro the activity of human TNF and is efficacious in many in vivo models of inflammation, including arthritis.
产品形式:蛋白原液。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
质量标准:
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test:…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件:-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件:干冰运输
使用建议:
meilunbio提供的产品为蛋白原液形式。每种装于冻存管中,单抗质量为标示数量1MG或者5MG,体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释,溶剂建议用去离子无菌水(meilunbio货号MA0028,去离子无菌水(细胞培养用水))或者PBS(meilunbio货号MA0015PBS(1X),细胞培养级)。
不建议使用含有防腐成分的稀释液进行稀释,会增加细胞或者动物毒性。
稀释前,计算加入多少体积溶剂,请参考购买批次质检单上蛋白浓度,或者询问我司,
举例,质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg(质量)/50mg/ml(浓度)=0.1ML,
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值,比如单次给药0.5MG,对应蛋白原液给药体积为10ul,建议稀释后,提高给药体积降低误差,因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液,可于2-8度冷藏避光保存不超过2周,不建议长期储存。
避免反复冻融,每次冻融蛋白活性会降低约5%左右。
生物活性(仅来自于公开文献,不保证其有效性)
描述
|
Etanercept inhibits in vitro the activity of human TNF and is efficacious in many in vivo models of inflammation, including arthritis. |
靶点 |
TNF |
Application |
Etanercept competitively inhibits the binding of both TNF-α and TNF-β (lymphotoxin-α) to cell surface TNF receptors, rendering TNF biologically inactive. It also modulates indirectly different biological responses that are induced or regulated by TNF, such as the expression of adhesion molecules E-selectin and to a lesser extent intercellular adhesion molecule 1 (ICAM-1), the production of interleukin-6 (IL-6) and matrix metalloproteinase 3 (MMP-3) (stromelysin), as well as IL1. |
美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
产品编号
|
品名. |
Target |
MB2806 |
aflibercept |
VEGFR |
MB2786 |
Alemtuzumab |
CD52 |
MB2787 |
Alirocumab |
PCSK9 |
MB2789 |
Avelumab |
PDL-1 |
MB2790 |
Atezolizumab |
PDL-1 |
MB2791 |
Bevacizumab |
VEGF |
MB2792 |
Cetuximab |
EGFR |
MB2803 |
Daratumumab |
CD38 |
MB2794 |
Denosumab |
RANK Ligand |
MB2023 |
Eculizumab |
补体蛋白(C5) |
MB2784 |
Adalimumab |
TNF-α |
MB2797 |
Evolocumab |
PCSK9 |
MB2773 |
Infliximab |
TNF-α |
MB2769 |
Ipilimumab |
CTLA-4 |
MB2772 |
Matuzumab |
EGFR |
MB2766 |
Mepolizumab |
IL-5 |
MB2767 |
Nivolumab |
PD-1 |
MB2774 |
Obinutuzumab |
CD20 |
MB2776 |
Ofatumumab |
CD20 |
MB2777 |
Omalizumab |
IgE |
MB2781 |
Panitumumab |
EGFR |
MB2761 |
Pembrolizumab |
PD-1 |
MB2762 |
Pertuzumab |
HER2 |
MB2763 |
Ranibizumab |
VEGFR |
MB2938 |
Ramucirumab |
VEGFR |
MB2749 |
Rituximab |
CD20 |
MB2757 |
Secukinumab |
IL-17 |
MB2751 |
Tocilizumab/Atlizumab |
IL-6 receptor |
MB2753 |
Trastuzumab |
ErbB2 |
MB2758 |
Ustekinumab |
IL-12 |
用途及描述:仅供科研,严禁用于人体(For R&D Only)
我司所售出产品仅供于科研研究用途(非临床科研研究),每次销售产品行为都适用于我司网上所列明的通用销售条款。